Job offer: a new vaccine strategy against SARS-CoV-2
The Angiogenesis Laboratory developed immuno-Boost (iBoost), a technology that allows the production of vaccines against self-antigens in the tumor vasculature. This strategy aims at inducing immune responses against low- or non-immunogenic antigens. SARS-CoV-2 has evolved mechanisms to escape immunity as well. While the spike protein S is majorly immunogenic, antibody responses to the immunodominant epitopes are not protective. Critical epitopes seem to be protected against immunity by conformational and proteolytic events. The Angiogenesis Laboratory secured major funding to design a targeted vaccine against epitopes that are critical for virus entry into cells, for therapeutic and preventive treatment. The approach to target conserved sequences aims to protect against future viruses as well.
Do you have your PhD-degree (soon) and are you interested in the project? Please contact Prof. Arjan Griffioen, email@example.com.